Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer CEO Read Will Pass The Torch To Bourla In 2019

Executive Summary

Chief Operating Officer Albert Bourla will succeed Ian Read as CEO of Pfizer, taking over the top spot at a steady point in the big pharma's evolution. Bourla's near-term challenges will be navigating the loss of Lyrica and the changing US health care dynamics.

Advertisement

Related Content

On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019
On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019
Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Stronger Together: Pfizer Decides Against A Split
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone
Zoetis raises $2.2bn in IPO but other pharma majors to retain animal health
Pfizer Turns To Insider Ian Read To Lead Into Post-Lipitor Era

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123927

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel